Using colistimethate sodium in complex therapy of cystic fibrosis in children under 6 years of age

Early and adequate antibacterial therapy of airway infections in patients with cystic fibrosis (CF) may lead to decrease in chronic inflammation, delay the worsening of pulmonary function, and prevent the selection of resistant bacteria. Inhaled forms of antibiotics, which can help to achieve high concentrations of drug in airways and minimize systemic adverse reactions, are particularly important when treating children under 6 years of age. Purpose. To evaluate effectiveness of combined therapy and tolerability of therapy with inhaled colistimethate sodium when treating exacerbations of infectious process in children with cystic fibrosis under 6 years of age. Methods. A retrospective analysis of medical records of patients with CF and infections caused by Pseudomonas aeruginosa who were admitted to pulmonology department of Federal State Autonomous Institution “National Medical Research Center for Children’s Health” of the Ministry of Health of the Russian Federation from June of 2021 to March of 2023 and who were treated with inhaled colistimethate sodium. Results. 20 courses of therapy in 17 patients with cystic fibrosis under 6 years of age were recorded. Mean duration of treatment was 10.4 days (4 – 19 days). There were no adverse reactions that led to discontinuation of the treatment. Clinical and microbiological effectiveness of the combined therapy was 60%. Conclusion. Therapy of exacerbations of airway infections caused by P. aeruginosa with inhaled colistimethate sodium was well tolerated by patients under 6 years of age. No adverse drug reactions were reported.

1. Worlitzsch D., Tarran R., Ulrich M. et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J. Clin. Invest. 2002; 109 (3): 317–325. DOI: 10.1172/JCI0213870.

2. Kondratyeva Y. I., Krasovskiy S.A., Starinova M.A. et al., eds. [Cystic fibrosis patients registry in Russian Federation, 2020]. Moscow: Medpraktika-M; 2022. Available at: https://api.med-gen.ru/site/assets/files/51107/site_registre_2020.pdf (in Russian).

3. Rutter W.C., Burgess D.R., Burgess D.S. Increasing incidence of multidrug resistance among cystic fibrosis respiratory bacterial isolates. Microb. Drug Resist. 2017; 23 (1): 51–55. DOI: 10.1089/mdr.2016.0048.

4. Cystic Fibrosis Foundation. Patient Registry 2021 Annual Data Report. Bethesda, Maryland; 2022. Available at: https://www.cff.org/sites/default/files/2021-11/Patient-Registry-Annual-Data-Report.pdf

5. Döring G., Flume P., Heijerman H. et al. Consensus study G. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J. Cyst. Fibros. 2012; 11 (6): 461–479. DOI: 10.1016/j.jcf.2012.10.004.

6. Ryan C., Ross S., Davey P. et al. Prevalence and causes of prescribing errors: the PRescribing outcomes for trainee doctors engaged in clinical training (PROTECT) study. PLoS One. 2014; 9 (1): e79802. DOI: 10.1371/journal.pone.0079802.

7. Mogayzel P.J., Naurckas E.T., Robinson K.A. et al. Cystic fibrosis foundation pulmonary guideline: pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Ann. Am. Thorac. Soc. 2010; 11 (10): 1640–1650. DOI: 10.1513/AnnalsATS.201404-166OC.

8. Koerner-Rettberg C., Ballmann M. Colistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapy. Core Evid. 2014; 9: 99–112. DOI: 10.2147/CE.S64980.

9. Evans M.E., Feola D.J., Rapp R.P. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann. Pharmacother. 1999; 33 (9): 960–967. DOI: 10.1345/aph.18426.

10. Rogers M.J., Cohen J. Comparison of the binding of gram-negative bacterial endotoxin by polymyxin B sulphate, colistin sulphate and colistin sulphomethate sodium. Infection. 1986; 14 (2): 79–81. DOI: 10.1007/BF01644448.

11. Gaibani P., Lombardo D., Lewis R.E. et al. In vitro activity and postantibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates. J. Antimicrob. Chemother. 2014; 69 (7): 1856–1865. DOI: 10.1093/jac/dku065.

12. Biswas S., Brunel J.M., Dubus .J.C. et al. Colistin: an update on the antibiotic of the 21st century. Expert Rev. Anti Infect. Ther. 2012; 10 (8): 917–934. DOI: 10.1586/eri.12.78.

13. Taccetti G., Francalanci M., Pizzamiglio G. et al. Cystic fibrosis: recent insights into inhaled antibiotic treatment and future perspectives. Antibiotics (Basel). 2021; 10 (3): 338. DOI: 10.3390/antibiotics10030338.

14. Alkhoury R., Kinkar E., Nokhbeh R., Saleh M.T. Monotherapy versus combination therapy for the treatment of Pseudomonas aeruginosa in cystic fibrosis patients. J. Antibiot. Res. 2018; 2 (1): 105. DOI: 10.15744/2574-5980.2.105.

15. Ratjen F., Moeller A., McKinney M.L. et al. Eradication of early P. aeruginosa infection in children < 7years of age with cystic fibrosis: the early study. J. Cyst. Fibros. 2019; 18 (1): 78–85. DOI: 10.1016/j.jcf.2018.04.002.

16. Ministry of Health of the Russian Federation. [Cystic fibrosis (cystic fibrosis): clinical guidelines]. 2021. Available at: https://cr.minzdrav.gov.ru/schema/372_2 (in Russian).

17. Ministry of Health of the Russian Federation. [Order No.835n “On the assessment of the standard of medical care for children with cystic fibrosis (cystic fibrosis) (diagnosis, treatment and dispensary observation)”]. 2021. Available at: https://docs.cntd.ru/document/608494977 (in Russian).